2000年7月28日
Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts
Life Sciences
- ,
- ,
- ,
- ,
- 巻
- 67
- 号
- 10
- 開始ページ
- 1243
- 終了ページ
- 1250
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/S0024-3205(00)00716-5
We investigated the effects of nafamostat mesilate, a synthetic protease inhibitor clinically used for patients with pancreatitis or disseminated intravascular coagulopathy, on NO synthesis and apoptosis in lipopolysaccharide (LPS)-treated human trophoblasts. Nafamostat mesilate or aminoguanidine, an inhibitor of NO synthase, suppressed NO synthesis and apoptosis in trophoblasts induced by LPS. Both agents also suppressed matrix metalloproteinase-2 activity induced by LPS. LPS also stimulated secretion of IL-6 and IL-8 in cultured trophoblasts, which was suppressed by nafamostat mesilate. Protease inhibitors including nafamostat mesilate may be therapeutic agents for chorioamnionitis and various diseases including septic shock, ischemia-reperfusion injury in brain and heart, graft rejection, and acute phase inflammatory diseases, in which overproduction of NO or peroxynitrite is involved in tissue injury. (C) 2000 Elsevier Science Inc.
- リンク情報
- ID情報
-
- DOI : 10.1016/S0024-3205(00)00716-5
- ISSN : 0024-3205
- PubMed ID : 10954057
- SCOPUS ID : 0034725839